This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (3)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Pain  • Rheumatology  • Musculoskeletal Syndromes (Chronic Fatigue, Gulf War)  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Rajkumar et al¹ reported that thalidomide (Thalomid; Celgene Corporation; Warren, NJ), prescribed for newly diagnosed multiple myeloma, led to unexpected improvement and near resolution of reflex sympathetic dystrophy in a woman with a 3-year history of the disorder. We report on our recent clinical experience using thalidomide to treat reflex sympathetic dystrophy, better known as complex regional pain syndrome (CRPS). This disorder is characterized by neuropathic pain, allodynia, edema, autonomic dysfunction, disordered movements, dystrophy, and atrophy.²

Independently, we treated 42 patients who satisfied the International Association for the Study of Pain definition of CRPS with thalidomide.³ Institutional review board approval was obtained at 2 institutions (Mayo Clinic, Rochester, Minn [K.B.], and St Elizabeth's Hospital, Youngstown, Ohio [E.C.]); at the third institution (Drexel University College of Medicine, Philadelphia, Pa [R.J.S.]), informed consent was obtained from all study participants according to the Declaration of Helsinki. All patients had long-standing disease, in whom . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?